MARKET

CSTL

CSTL

Castle Biosciences
NASDAQ
26.75
-0.07
-0.26%
Closed 16:08 02/08 EST
OPEN
26.53
PREV CLOSE
26.82
HIGH
28.00
LOW
26.39
VOLUME
132.27K
TURNOVER
--
52 WEEK HIGH
48.40
52 WEEK LOW
15.58
MARKET CAP
704.90M
P/E (TTM)
-13.0170
1D
5D
1M
3M
1Y
5Y
Insider Sell: Castle Biosciences
Insider Sell: Castle Biosciences
MT Newswires · 5d ago
Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M
Seeking Alpha · 01/09 07:28
Castle Biosciences Expects to Meet or Surpass Top End of 2022 Revenue Guidance Range
Castle Biosciences Expects to Meet or Surpass Top End of 2022 Revenue Guidance Range
MT Newswires · 01/09 05:35
Castle Biosciences Announced Preliminary FY 2022 Total Revenue Expected To Meet Or Exceed Top End Of Guided Range Of $132M–137M vs 135.47M Est
Benzinga · 01/09 00:18
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target
MT Newswires · 01/05 09:07
Castle Biosciences Receives Accreditation From The College Of American Pathologists For Its Pittsburgh Clinical Laboratory
Benzinga · 11/21/2022 12:09
Looking Into Castle Biosciences's Return On Capital Employed
Benzinga · 11/16/2022 14:47
BRIEF-Castle Biosciences Presents Data Showing The Clinical Utility Of Decisiondx In Carcinoma Tumors
Reuters · 11/15/2022 12:23
More
About CSTL
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Its products include DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, TissueCypher and IDgenetix. DecisionDx-Melanoma is a gene expression profile test developed to identify the risk of metastasis in patients with invasive cutaneous melanoma.

Webull offers kinds of Castle Biosciences Inc stock information, including NASDAQ:CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.